The previous lesson showed how nicotine replacement therapy (NRT) can ease withdrawal without exposing someone to cigarette smoke. Other medicines can support a quit attempt without supplying nicotine. This lesson compares varenicline, bupropion, and cytisine: what each does, what the evidence says about sustained quitting, and what can limit its use. Cytisine is considered only where it is locally approved or available.
Three medicines, different approaches
Dependence involves both withdrawal when nicotine is absent and the rewarding effect of smoking when nicotine returns. Varenicline and cytisine act at nicotine-responsive receptors in the brain. They partly activate those receptors, which can ease cravings and withdrawal, while reducing some of the reward from smoking. Neither is nicotine replacement.
Bupropion takes a different route. It is also used as an antidepressant, but its smoking-cessation effect does not depend on treating depression. It affects chemical signaling in the brain; precisely how that helps people stop smoking is not fully established. It, too, contains no nicotine.
The World Health Organization (WHO) places these medicines alongside NRT as evidence-based cessation options. Its recommendations do not mean that everyone should take a medicine, or that one choice suits everyone. Availability, medical history, likely side effects, and personal preference all matter.
WHO clinical treatment guideline for tobacco cessation in ...
Read the WHO's treatment recommendation to establish which medicines have a place in cessation care before comparing their differences.
In Section 3.3, "Pharmacological interventions delivered in both clinical and community settings," go to Subsection 3.3.1, "Recommendations," on p. 17. Read recommendation 4, beginning with the treatment options and ending at the statement of evidence certainty. Notice that cytisine is included, while varenicline, NRT, and bupropion are named as first-line options.
A medicine can reduce the biological pressure to smoke; it cannot, by itself, rearrange a smoking break or prepare someone for an offer of a cigarette. That is why treatment can be paired with the counseling and other behavioral support covered earlier in the course.
How their roles differ
Varenicline is a partial activator of a receptor involved in nicotine dependence. By providing some receptor activity while reducing nicotine’s ability to produce its usual rewarding effect, it addresses both withdrawal and reinforcement from smoking. It is generally started before the planned quit date and taken for a course of treatment under local prescribing directions. It does not guarantee that smoking will feel unrewarding or that every craving will disappear.
Bupropion can also reduce the difficulty of stopping, but it does not work by occupying nicotine receptors. A clinician may consider it when its overall benefits and risks fit the person’s circumstances. Like varenicline, it is generally begun before the quit date rather than saved for an urge that has already arrived. It is not a fast-acting substitute for the gum or lozenge discussed in the previous lesson.
Cytisine is a plant-derived partial activator of nicotine receptors. Its broad approach is similar to varenicline’s, but it is a different medicine with its own treatment instructions and evidence base. A plant origin does not make it automatically safe for everyone. Its approval and availability vary by location, so it should not be assumed to be an option in every quit plan.
The National Cancer Institute (NCI) describes the mechanisms and research in more technical terms. Read the specified passages for the core distinctions; there is no need to memorize doses or every trial result.
Cigarette Smoking: Health Risks and How to Quit (PDQ®) - NCI
Read the NCI's medicine descriptions to connect each treatment's role with its observed benefits and common adverse effects.
In the page's discussion of cessation medicines, find the bupropion paragraph beginning "Also used as an antidepressant." Read the bupropion passage through its side-effect discussion. Next find the paragraph beginning "Varenicline is a selective partial agonist." Read the mechanism, then continue through the study comparisons to the paragraph beginning "The results of a synthesis of 41 randomized trials." Read the synthesis there. Focus on the distinction between single-form and dual NRT. Finally, in the subsection "Cytisine," read from its description through the closing side-effect sentence, immediately before "Other agents." Notice both its benefit over no active medicine and the uncertainty in comparisons with varenicline.
Comparing benefits without declaring a universal winner
The useful outcome is sustained quitting, not simply feeling fewer cravings on the first day. Across trials, all three medicines help more people quit than placebo or no pharmacological treatment. The comparisons between medicines need more care:
| Medicine | Role in a quit attempt | Important evidence distinction |
|---|---|---|
| Varenicline | Reduces withdrawal and some of smoking’s rewarding effect | On average, more effective than bupropion or single-form NRT; no clear advantage established over combination NRT |
| Bupropion | Non-nicotine aid that can make quitting more achievable | Better than placebo; on average, less effective than varenicline |
| Cytisine | Nicotine-receptor partial activator, where locally available | Better than placebo; comparisons with varenicline remain less certain |
“More effective on average” describes study groups, not a prediction for one person. Likewise, no clear difference is not proof that two treatments work identically. Trials may be too small or their estimates too imprecise to settle a comparison. Cytisine illustrates this particularly well: evidence supports its use, but it would overstate the evidence to call it definitively equal or inferior to varenicline.
Read the WHO's benefit–harm conclusions after the NCI descriptions. They put effectiveness alongside the adverse effects that influence treatment choice.
WHO clinical treatment guideline for tobacco cessation in ...
Return to the WHO guideline for its concise assessment of what each medicine gains and what may limit it.
In Subsection 3.3.3.6, "Conclusions," spanning pp. 19–20, find the bullet beginning "There is high-certainty evidence that bupropion increases long-term smoking cessation rates." Read the medicine conclusions from that bullet through the cytisine benefit–harm discussion and the start of its final decision statement. Focus on the named common effects and on how the certainty of evidence differs across the three medicines; the numerical risk measures are not needed for this lesson.
Common limitations and the clinician’s role
Tolerability can determine whether an effective medicine is useful in practice. Nausea, unusual dreams, and insomnia are common concerns with varenicline. Bupropion can cause insomnia, dry mouth, or dizziness. Cytisine can cause nausea, vomiting, or sleep disturbance. These effects are not inevitable, but they are worth discussing rather than silently abandoning treatment. A clinician or pharmacist can help assess an effect and advise whether a change is appropriate.
Suitability matters as much as tolerability. Bupropion has a seizure-risk consideration and may be unsuitable for some people with seizure disorders or a history of certain eating disorders. Other health conditions, medicines, pregnancy, and changes in mental health can also affect treatment decisions. Even where cytisine is obtainable without a prescription, local availability is not a substitute for checking whether it is appropriate. The next lesson examines situations calling for clinician or pharmacist review in more detail.
These medicines are usually planned as courses of treatment, often begun before stopping cigarettes; they are not interchangeable remedies to take only when a craving strikes. Instructions, duration, and access differ by medicine and jurisdiction. A clinician-guided choice therefore means weighing evidence against the individual’s circumstances, checking local product guidance, and arranging follow-up if adverse effects or persistent cravings interfere with the attempt. Behavioral support remains useful whichever treatment is chosen.
Key takeaways
Varenicline and cytisine partly activate nicotine-responsive receptors; bupropion works differently and its precise cessation mechanism is not fully known. All three improve the chance of sustained quitting compared with no active medicine. Varenicline generally outperforms bupropion and single-form NRT in trials, while comparisons with combination NRT—and between cytisine and varenicline—require more cautious interpretation. Side effects, medical suitability, and local approval or availability prevent a single ranking from serving as everyone’s treatment plan.
The next lesson looks more closely at when a clinician or pharmacist should review treatment choices, including pregnancy, relevant health conditions, and possible changes to other medicines.